ood morning, everyone, and welcome to the middle of the week. There’s just a few more days until the rush of meetings and deadlines and paperwork can be put aside for a bit of late-summer relaxation. So, in the meantime, keep plugging away. I’m Rebecca Robbins, and I’m a reporter for STAT, filling in again to bring you a menu of headlines from the world of pharma. Shall we get started?
Teva (TEVA) is looking for partners to help fund development of some of the drug compounds in its pipeline, Reuters informs us. The generic drug giant aims to reduce its debt load by more than $5 billion this year.